

Press release October 26, 2021, 08.30 CET.

Sedana Medical's Nomination committee appointed

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 10, 2021, the Chairman of the Board has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.

Sedana Medical's Nomination Committee for the 2022 Annual General Meeting consists of:

- Thomas Eklund, Chairman of the Board
- Karl Tobieson, appointed by Linc AB
- Malin Björkmo, appointed by Handelsbanken Fonder
- Jan Andersson, appointed by Swedbank Robur Fonder

Karl Tobieson is appointed chairman of the Nomination Committee.

The Nomination Committee represents 26.6 per cent of all voting rights in the company as of September 30, 2021. The Nomination Committee shall submit proposals for resolution by the 2022 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

Shareholders wishing to submit proposals to Sedana Medical's Nomination Committee can do so by e-mail to ir@sedanamedical.com by January 31, 2022.

For additional information, please contact:

Nomination Committee Chairman, Karl Tobieson

Phone: +46 70 935 85 74

E-mail: karl.tobieson@linc.se

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.

The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.